• FAQ
  • Sitemap
  • Legal Notices
  • Contacts
  • Hrv
  • About HALMED
  • Medicinal Products
  • Medical Devices
  • Distribution, Manufacturing and Inspection
  • Pharmacovigilance
  • News and Educations

Pharmacovigilance

  • Homepage
  • Pharmacovigilance
  • New Safety Information

Meeting highlights from the CMDh meeting in December 2016

27.12.2016

more

Direct healthcare professional communication emphasizing that Ammonaps (sodium phenylbutyrate) tablets and granules should only be used when there is no alternative treatment

20.12.2016

more

Meeting highlights from the CHMP meeting in December 2016

19.12.2016

more

Start of a review concerning the conduct of studies at Micro Therapeutic Research Labs, India

16.12.2016

more

Recommendations for screening for hepatitis B before treatment with direct-acting antivirals for hepatitis C

16.12.2016

more

Meeting highlights from the PRAC meeting in November 2016

02.12.2016

more

PRAC warns of risk of hepatitis B re-activation in patients treated with direct-acting antivirals for hepatitis C

02.12.2016

more

EMA to review certain injectable medicines for treatment of acute allergic reactions

02.12.2016

more

Meeting highlights from the CMDh meeting in November 2016

16.11.2016

more

Meeting highlights from the CHMP meeting in November 2016

14.11.2016

more

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • »

For Patients and Public

For Health Care Professionals

For Industry Representatives

  • What is Pharmacovigilance?
  • How to Report an Adverse Drug Reaction
  • New Safety Information
    • Archive 2022
    • Archive 2021
    • Archive 2020
    • Archive 2019
    • Archive 2018
    • Archive 2017
    • Archive 2016
    • Archive 2015
    • Archive 2014
    • Archive 2013
    • Archive 2012
    • Archive 2011
    • Archive 2010
    • Archive 2009
  • Direct Healthcare Professional Communication
  • Risk minimisation measures (RMM)
  • List of serious adverse reactions
  • Information for Marketing Authorisation Holders
  • Adverse Drug Reactions Reports
  • Pandemic Influenza A/H1N1
  • Information for Marketing Authorisation Holders - Electronic Transmission of ICSRs
  • Seal for Marking of Important Safety Information
  • Pharmacovigilance and Risk Assessment Committee (PRAC) - Links
  • Medicinal Products under Additional Monitoring
  • Signal management
  • Submission of Application Documentation for Assessment of Non-Interventional Trials
  • SCOPE Project
  • Access to Databases of Suspected ADRs
  • Homepage
  • FAQ
  • Sitemap
  • Legal Notices
  • Contacts
  • About HALMED
  • Medicinal Products
  • Medical Devices
  • Distribution, Manufacturing and Inspection
  • Pharmacovigilance
  • News and Educations
  • HALMED for:
  • Patients and Public
  • Health Care Professionals
  • Industry Representatives

Copyright © 2007-2023. Agency for Medicinal Products and Medical Devices of Croatia.
All rights reserved.